Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022076442> ?p ?o ?g. }
Showing items 1 to 58 of
58
with 100 items per page.
- W2022076442 abstract "Background Non-localized renal cell carcinoma (RCC) carries a poor prognosis that imposes a serious risk of mortality upon patients. Traditionally, interleukin-2 and interferon-(alpha) were utilized in this setting with limited improvement in cancer-specific survival and high toxicity; however, newer agents such as Sunitinib, Sorafenib, Bevacizumab and Temsirolimous have demonstrated great potential and provide a new frontier in the management of high-risk RCC. Methods and Methods Pubmed and OVID Medline databases were queried for English articles from 1950 to December 2008 using the keywords “renal cell carcinoma” AND “high risk” and “renal cell carcinoma” AND “neoadjuvant”. Articles from these searches and the references of relevant articles were utilized. Articles published between 1996 and 2008 were included in this review. Results Risk stratification is imperative for optimal patient selection in adjuvant, neoadjuvant and research settings. Utilization of interferon-alpha and interleukin-2 has not demonstrated improved disease-free survival in the adjuvant setting. A number of adjuvant vaccines have also failed to demonstrate improved survival. The adjuvant role of targeted small molecule inhibitors such as sorafenib, sunitinib and temsirolimus is currently under investigation in phase III trials. Sporadic case reports have demonstrated promising results with neoadjuvant use of these agents and a pilot study of neoadjuvant temsirolimus is currently underway at our centre. Conclusion The role, efficacy and toxicity of adjuvant and neoadjuvant targeted small molecule inhibitors in high-risk RCC remains to be delineated. Ideally, clinicians will be able to identify high-risk patients and offer treatment to those who would benefit most from adjuvant and neoadjuvent therapy while minimizing toxicity in low-risk patients. Key words : renal cell carcinoma, adjuvant therapy, neoadjuvant therapy, neo-adjuvant, review" @default.
- W2022076442 created "2016-06-24" @default.
- W2022076442 creator A5013185325 @default.
- W2022076442 date "2009-05-06" @default.
- W2022076442 modified "2023-09-25" @default.
- W2022076442 title "Adjuvant and Neoadjuvant Small Molecule Targeted Therapy" @default.
- W2022076442 doi "https://doi.org/10.3747/co.v16i0.415" @default.
- W2022076442 hasPublicationYear "2009" @default.
- W2022076442 type Work @default.
- W2022076442 sameAs 2022076442 @default.
- W2022076442 citedByCount "2" @default.
- W2022076442 countsByYear W20220764422015 @default.
- W2022076442 crossrefType "journal-article" @default.
- W2022076442 hasAuthorship W2022076442A5013185325 @default.
- W2022076442 hasBestOaLocation W20220764421 @default.
- W2022076442 hasConcept C121608353 @default.
- W2022076442 hasConcept C126322002 @default.
- W2022076442 hasConcept C143998085 @default.
- W2022076442 hasConcept C2777863537 @default.
- W2022076442 hasConcept C2777982462 @default.
- W2022076442 hasConcept C2778292576 @default.
- W2022076442 hasConcept C2781230642 @default.
- W2022076442 hasConcept C530470458 @default.
- W2022076442 hasConcept C60644358 @default.
- W2022076442 hasConcept C70721500 @default.
- W2022076442 hasConcept C71924100 @default.
- W2022076442 hasConcept C86803240 @default.
- W2022076442 hasConceptScore W2022076442C121608353 @default.
- W2022076442 hasConceptScore W2022076442C126322002 @default.
- W2022076442 hasConceptScore W2022076442C143998085 @default.
- W2022076442 hasConceptScore W2022076442C2777863537 @default.
- W2022076442 hasConceptScore W2022076442C2777982462 @default.
- W2022076442 hasConceptScore W2022076442C2778292576 @default.
- W2022076442 hasConceptScore W2022076442C2781230642 @default.
- W2022076442 hasConceptScore W2022076442C530470458 @default.
- W2022076442 hasConceptScore W2022076442C60644358 @default.
- W2022076442 hasConceptScore W2022076442C70721500 @default.
- W2022076442 hasConceptScore W2022076442C71924100 @default.
- W2022076442 hasConceptScore W2022076442C86803240 @default.
- W2022076442 hasIssue "S1" @default.
- W2022076442 hasLocation W20220764421 @default.
- W2022076442 hasOpenAccess W2022076442 @default.
- W2022076442 hasPrimaryLocation W20220764421 @default.
- W2022076442 hasRelatedWork W2018840920 @default.
- W2022076442 hasRelatedWork W2051447115 @default.
- W2022076442 hasRelatedWork W2059547176 @default.
- W2022076442 hasRelatedWork W2096393323 @default.
- W2022076442 hasRelatedWork W2402372578 @default.
- W2022076442 hasRelatedWork W2460051703 @default.
- W2022076442 hasRelatedWork W2487368545 @default.
- W2022076442 hasRelatedWork W2530130754 @default.
- W2022076442 hasRelatedWork W2804629409 @default.
- W2022076442 hasRelatedWork W3012289493 @default.
- W2022076442 hasVolume "16" @default.
- W2022076442 isParatext "false" @default.
- W2022076442 isRetracted "false" @default.
- W2022076442 magId "2022076442" @default.
- W2022076442 workType "article" @default.